

Dockets Management Branch  
Division of Management Systems and Policy  
Office of Human Resources and Management Services  
Food and Drug Administration  
5630 Fishers Lane, Room 1061, (HFA-305)  
Rockville, MD 20852.

Docket No. 02D-0325


The organizations and individuals signed below are writing to urge the FDA to support your Public Health Notification on the plasticizer di-(2-ethylhexyl)phthalate (DEHP) in medical devices with policies that will allow providers to implement its recommendations. In particular, we urge the FDA to require labeling of medical devices containing DEHP. Our comments are offered in response to the "Draft Guidance for Industry and FDA on Medical Devices Made With Polyvinylchloride (PVC) Using the Plasticizer di-(2-Ethylhexyl)phthalate (DEHP)" recently released for comment by your agency.

The National Toxicology Program review and the FDA's own Safety Assessment have found that exposure to DEHP during early stages of development may be harmful to the developing male reproductive system. That concern was identified at levels of exposure expected to occur during some routine uses of medical devices. High-risk groups include male fetuses, neonates, and peripubertal males.


Following from these findings, the FDA, in its recent Public Health Notification, identified the following procedures as posing the highest risk of exposure to DEHP: exchange transfusions in neonates; ECMO in neonates; total parenteral nutrition (TPN) in neonates (with lipids in the bag); enteral nutrition in neonates and adults; aggregate doses in patients receiving heart transplant or undergoing coronary artery bypass graft surgery; massive infusion of blood into trauma patients; and transfusion in adults undergoing ECMO. The Public Health Notification further recommends considering alternatives to DEHP-containing devices when high-risk procedures are to be performed on male neonates, pregnant women who are carrying male fetuses, and peripubertal males

In its draft Guidance subsequently released to the public, the FDA identified a list of device categories regulated by its Center for Devices and Radiological Health that may contain PVC components and therefore the plasticizer DEHP. Currently, there are only a handful of devices that are labeled.

The FDA's Guidance recommends that manufacturers consider the feasibility of replacing PVC containing DEHP with either alternative materials or plasticizers, or using coatings that may minimize patient exposure to DEHP. If manufacturers choose not to redesign or reformulate their DEHP-containing products, the FDA recommends, but does not require, that manufacturers label their products so that users will be able to identify those products that contain DEHP.



02D-0325



19

The voluntary approach adopted by the FDA does not provide assurance that devices will be labeled, nor that practitioners will have enough information to make informed decisions. If manufacturers choose not to label their DEHP-containing products, medical device users would be left in the unfortunate position of not knowing whether or not they were using a DEHP-containing product, making protection of vulnerable patients very difficult. As individuals and organizations concerned for the public health, we believe that without FDA requiring it, many manufacturers will not notify health care providers of the presence of DEHP in medical devices. Further, obtaining information from manufacturers about whether or not a product contains DEHP is not always straightforward.

Further, the information already published by the FDA regarding the potential harm of DEHP appears to meet the FDA's definition of when a label should be required - that is, when usage by or affecting children may be harmful to health. The population affected by the needed labeling is not insignificant. Pregnant women, women who may be pregnant, peripubertal males, and neonates constitute a large patient population at risk from DEHP exposure.

We urge the FDA to craft policies that allow practitioners to implement the Public Health Notification issued by your agency. Without labeling, we find it difficult to understand how health care providers are to carry out the FDA recommendations. As members of the environmental and public health community, we recognize the responsibility that health care providers have to protect the health of their patients. We urge the FDA to give practitioners the tools they need to protect the health of their patients.

Moreover, we believe suppliers and distributors should also be encouraged to make information about DEHP and/or PVC readily available in catalogs and other materials used in the marketing of medical devices. Without this information, purchasers and health care providers will not be able to make informed purchasing decisions necessary for protecting the health of patients.

Sincerely,

Ken P. Scott, CFA  
Portfolio Manager and Social Research Analyst  
Walden Asset Management  
Boston, MA

Alicia Culver, Director, Chemical Hazards Prevention Program  
INFORM, Inc.  
New York, NY

Janet Nudelman  
Director of Program  
The Breast Cancer Fund  
San Francisco, CA

Barbara Brenner  
Breast Cancer Action  
San Francisco, CA

John Leigh  
Waste Management Coordinator  
Dartmouth-Hitchcock Medical Center  
Lebanon, NH

Neha Patel, Program Manager  
Oregon Center for Environmental Health

Monica Rohde Buckhorn  
Center for Health, Environment and Justice

Michael Green, Executive Director & Mamta Khanna, Program Director  
(HCWH)  
Center for Environmental Health  
Oakland, CA

Clarence R. Dunn, Chairman  
The Greater Cleveland Coalition of a Clean Environment  
Eucli, Ohio

Chris Trepal, Executive  
Earth Day Coalition,

Rich Whate  
Canadian Coalition for Green Health Care

Bryony Schwan,  
National Campaigns Director  
Women's Voices for the Earth  
Missoula, MT

Tom Badrick  
Recycling Specialist  
Legacy Health System  
Portland, OR

Jorge Emmanuel, PhD  
The Environment & Engineering Research Group  
Rodeo, CA

Tracey Easthope, MPH  
Director, Environmental Health Project  
Ecology Center  
Ann Arbor, MI